
Frances Valdes-Albini, MD, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses ongoing clinical trials of patients with HER2-positive breast cancer.

Your AI-Trained Oncology Knowledge Connection!


Frances Valdes-Albini, MD, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses ongoing clinical trials of patients with HER2-positive breast cancer.

Frances Valdes-Albini, MD, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the FDA approval of adjuvant pertuzumab (Perjeta) in patients with HER2-positive breast cancer.

Published: April 12th 2018 | Updated:

Published: June 7th 2018 | Updated: